Abstract LBA30
Background
For shrinkage of RAS/BRAF WT tumors, anti-EGFR antibodies combinated with triplet chemotherapy (CT) regimen have shown promising results in phase I-II trials. Ultrasensitive cirDNA analysis as those with IntPlex® technology might result in better selection of super-responders to anti-EGFR-based therapies. Thus, the aim of PANIRINOX was studying the complete response (CR) rate obtained with P plus a tri-CT regimen (FOLFIRINOX = Arm A) or a standard bi-CT (mFOLFOX6 = Arm B) in pts with cirDNA-based RAS/BRAF V600E WT unresectable mCRC tumors.
Methods
In this randomised non-comparative multicentric phase II trial, pts were assigned in a 2:1 ratio in arm A/B (12 cycles max) in 2 different strata (str) according to disease extent (str 1: liver limited /str2: non-liver-limited). Primary endpoint was the CR rate according to RECIST 1.1 (central review) and CEA normalization (Fleming’s one-step design, one-sided a=5%, b=10%, H0: 3%; H1: 12%; 60 pts in Arm A needed with at least 4 successes; Arm B as internal control). Secondary endpoints included progression-free and overall survival (PFS and OS).
Results
From 10/2017 to 07/2022, 78/33 pts were assigned in arm A/B in str2. Main characteristics were (arm A/B): median age 64/62 yo; males 67/45%; PS0 63/42%; left-sided 81/79%; synchronous metastases 85/87%; >1 metastatic site 82/72%. The table lists CR, PFS and OS in evaluable pts. Main grade≥3 treatment-related adverse events were (arm A/B): diarrhea 39/9%, peripheral neuropathy 22/24%, skin 18/24%. Table: LBA30
Arm A FOLFIRINOX+P (N=65) | Arm B mFOLFOX6+P (N=27) | |
Median follow-up (months) [95% CI] | 32.0 [28.7; 32.3] | 30.4 [23.4; 35.7] |
Complete response (number) (%) [95% CI] | 5 7.7 [2.5; 17.0] | 2 7.4 [0.9; 24.3] |
Objective response rate (complete + partial radiological reponse) | 75.4% | 77.8% |
Median PFS (months) [95% CI] | 9.1 [8.1; 11.7] | 9.0 [7.5; 13.2] |
Median OS (months) [95% CI] | NR | 20.4 [15.1; NR] |
Conclusions
With 5 pts achieving CR in arm A and 95%CI including predetermined hypothesis in arm B, the study met its primary objective in str2. We confirm that genotyping tumors from cirDNA analysis is a relevant alternative to tissue before administrating anti-EGFR-based therapies in first line.
Clinical trial identification
EudraCT 2016-001490-33, NCT02980510.
Editorial acknowledgement
Legal entity responsible for the study
UNICANCER.
Funding
Amgen.
Disclosure
T. Mazard: Financial Interests, Personal, Advisory Board: Pierre Fabre, Pierre Fabre, Serivier, AAA; Financial Interests, Personal, Invited Speaker: Servier, Sanofi; Financial Interests, Personal, Other, Development of clinical cases for regional meetings: Merck Serono; Financial Interests, Institutional, Coordinating PI: Amgen; Non-Financial Interests, Other, development of guidelines about molecular testing in colorectal cancers: INCA; Other, travel grant: Pierre Fabre, Merck Serono, Sanofi. D. Botsen: Non-Financial Interests, Institutional, Training: Amgen, Sanofi, MSD, Merck Sarono, Pierre Fabre; Non-Financial Interests, Institutional, Coordinating PI: Servier. All other authors have declared no conflicts of interest.
Resources from the same session
560MO - Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial
Presenter: Pilar García Alfonso
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 558MO, 559MO and 560MO
Presenter: Jeanne Tie
Session: Mini oral session - Gastrointestinal tumours, lower digestive
Resources:
Slides
Webcast